Efficacy and safety of high-dose cabergoline in Parkinson's disease.

摘要: Objectives –  To assess the efficacy and safety of high-dose (up to 20 mg/day) cabergoline in Parkinson's disease (PD) patients with motor fluctuations and/or dyskinesias. Materials methods –  Thirty-four PD had up-titrated their levodopa (l-dopa) reduced over a maximum 20 weeks, followed by at least 6 weeks steady dosing. Primary endpoint was change mean hyperkinesia intensity final visit (week 26). Results –  Mean (± SD) increased from 6.43 ± 2.66 12.78 ± 5.67 mg/day l-dopa 606.6 ± 263.9 370.6 ± 192.5 mg/day. A significant reduction (P < 0.001) occurred baseline (day 0) week 26. Improvements ‘on dyskinesias’, dystonia (P < 0.05), time spent ‘severe off’ condition, severity ‘off’ periods as well clinical/patient global impression, health-related quality life were observed. Twenty-four drug-related adverse events recorded which four regarded serious. Conclusion –  High-dose tolerated provided improvements Parkinson symptomatology requirement for l-dopa.